Medicine as strategic power
India's pharmaceutical exports stood at about USD 30.47 billion in 2024-25, according to official data, and India remains one of the world's leading suppliers of generic medicines. PIB has described India as the largest global supplier of generic medicines, accounting for around 20 percent of global supply. India has also been recognised as a major vaccine producer. These numbers are not only industrial achievements; they are diplomatic assets.
The pharmacy of the world
India's pharma rise rests on cost-efficient manufacturing, skilled scientific manpower, process chemistry, a large domestic market and decades of generic competition. Indian firms supply medicines to regulated markets and developing countries alike. For many low- and middle-income nations, Indian generics are the difference between treatment and exclusion.
This is why the phrase 'pharmacy of the world' has strategic meaning. During HIV/AIDS treatment struggles, affordable generics changed global access. During COVID-19, vaccine production and supply became central to diplomatic narratives. In future pandemics, the ability to manufacture at scale will again determine who receives protection early and who waits.
Health diplomacy beyond charity
India's health diplomacy should not be reduced to donation diplomacy. Donations matter during emergencies, but lasting influence comes from reliable supply, regulatory credibility, technology partnerships, training, surveillance cooperation and manufacturing ecosystems. Countries trust suppliers that deliver consistently, meet quality standards and remain affordable.
This gives India a chance to build long-term relationships across Africa, Asia, Latin America and the Pacific. Health partnerships can support India's Global South leadership because they address everyday vulnerability. A country that helps lower medicine costs earns goodwill that defence deals alone cannot produce.
Strategic vulnerabilities
India's pharma strength also contains vulnerabilities. Dependence on imported active pharmaceutical ingredients from China remains a concern, especially for key starting materials and bulk drugs. Quality lapses by some manufacturers can damage the reputation of the entire sector. Regulatory scrutiny from the US, EU and WHO-linked procurement systems is rising. Price pressure in generics can reduce margins and discourage innovation.
If India wants pharma power to remain diplomatic power, it must treat quality as strategy. One contamination scandal can travel faster than years of goodwill. Stronger inspection systems, data integrity, pharmacovigilance, API resilience and investment in complex generics and biologics are essential.
Pandemic agreement and India's role
The WHO Pandemic Agreement makes India's role even more relevant. The debate over access to vaccines, diagnostics and treatments will require countries that can manufacture at scale and argue for equity. India can support a balanced model where innovation is rewarded but emergency access is not hostage to monopoly pricing.
India's negotiating position should connect its industrial capacity with Global South concerns. It can advocate regional manufacturing, voluntary licensing, transparent technology transfer, pooled procurement and predictable financing. It should also invest in domestic R&D so that it is not seen only as a low-cost manufacturer but as a source of innovation.
Economic diplomacy and market access
Pharma exports support India's economic diplomacy. Medicines create trade relationships, regulatory dialogues and standards cooperation. As countries seek to diversify supply chains away from excessive dependence on any single source, India can present itself as a trusted partner. This aligns with broader strategies around China+1, resilient supply chains and strategic autonomy.
However, market access will not be automatic. Rich countries may tighten quality rules, impose tariffs, encourage domestic production or use industrial policy to reshore critical medicines. Developing countries may build their own manufacturing capacity. India's advantage will depend on moving up the value chain while preserving affordability.
Counter-view: is India's leverage overstated?
The counter-view is that India's pharma diplomacy is often overstated. Many Indian firms operate in low-margin generics. The most profitable innovation remains concentrated in the US, Europe, Japan and increasingly China. India still imports important inputs. Domestic public-health spending and regulatory capacity do not always match its global rhetoric. These concerns are real.
But leverage does not require dominance in every segment. It requires relevance at critical points. In affordable generics, vaccines, manufacturing scale and Global South access, India is highly relevant. The task is to convert relevance into durable influence through quality, innovation and diplomacy.
What happens next
India's next opportunity lies in complex generics, biosimilars, mRNA platforms, vaccine R&D, diagnostics, digital health and API resilience. It should build strategic health partnerships with Africa and Southeast Asia, support regulatory capacity abroad and invest in rapid-response manufacturing for future outbreaks.
Pharma power strengthens India's position in global health diplomacy because health is where morality, markets and strategy meet. If India can provide affordable, high-quality and timely medical solutions, it will not merely sell medicines. It will shape the politics of survival.
From generics to strategic innovation
India's next challenge is to move from volume leadership to innovation depth. Generics will remain central, but future influence will also depend on biosimilars, complex injectables, gene therapies, mRNA platforms, diagnostics and platform technologies that can be rapidly adapted during outbreaks. The countries that control platforms will shape the pace of response.
Public policy should support R&D without abandoning affordability. Tax incentives, university-industry collaboration, regulatory speed, clinical-trial quality and predictable pricing rules can help. India should not choose between being affordable and innovative. It should aim to become the country that makes innovation affordable.
Quality as diplomacy
Quality is now a diplomatic issue. When Indian medicines save lives, India's reputation rises. When quality failures occur, rivals and regulators use them to question reliability. The sector therefore needs a culture of compliance that goes beyond paperwork. Data integrity, inspection transparency, recall systems and accountability are part of foreign policy because they shape trust in Indian supply.
Regulatory diplomacy should be strengthened. India can work with African and Asian regulators, support harmonisation and train inspectors. This creates markets, but it also creates a shared quality ecosystem in which India is seen as partner rather than mere exporter.
Health partnerships with the Global South
India should build long-term health compacts with regions that depend heavily on affordable medicines. These compacts can include supply guarantees, local manufacturing partnerships, scholarships, telemedicine, disease surveillance and emergency procurement channels. The aim should be to create resilience, not dependency.
Africa is especially important. A growing population, disease burden and expanding health markets make African partnerships central to the future of global health. India can compete not by imitating China's infrastructure model or the West's aid model, but by offering affordable health capability.
Editorial judgement
Pharma power is one of India's most tangible forms of soft power because it is measured in lives, not slogans. A tablet that a patient can afford is a diplomatic message more powerful than a communique.
The opportunity is large, but it is not guaranteed. India must protect quality, build innovation and align commercial strategy with global health equity. If it does, its pharma sector will become a pillar of twenty-first-century diplomacy.
API security and strategic autonomy
India's pharma diplomacy will remain vulnerable if critical inputs are dependent on concentrated foreign supply chains. Active pharmaceutical ingredients and key starting materials are the hidden foundations of medicine security. A disruption in APIs can weaken even a strong formulations industry.
Strategic autonomy in pharma therefore requires domestic API capacity, diversified imports, emergency reserves and incentives for critical molecules. The goal is not autarky. It is resilience.
Regulatory trust in developed markets
Access to regulated markets such as the US and EU depends on compliance. For Indian firms, regulatory trust is a commercial passport. Warning letters, data-integrity concerns or quality failures can close doors and damage brand India. High standards are not foreign pressure alone; they are the cost of global leadership.
India should strengthen its own regulator so that quality is assured at home before foreign regulators intervene. A respected domestic regulator would increase confidence in Indian medicines worldwide.
Pharma and India's Global South narrative
India's Global South narrative becomes credible when it offers practical solutions. Affordable medicines, vaccine partnerships and health-system training are concrete. They directly affect families, hospitals and governments. This makes pharma diplomacy more emotionally powerful than abstract geopolitical rhetoric.
The opportunity is to move from supplier to partner. India should help countries build procurement systems, cold chains, regulatory capacity and local production where viable. Partnership deepens influence more than one-time export success.
Final editorial line
India's pharma power will shape diplomacy only if scale is matched by trust. The world does not merely need cheap medicine; it needs reliable medicine from a country that understands health equity as strategy.
Research Sources Used
• PIB, India pharmaceutical exports 2024-25: https://www.pib.gov.in/PressReleasePage.aspx?PRID=2205547&lang=2®=3
• PIB, India pharmaceuticals in global healthcare: https://www.pib.gov.in/PressReleasePage.aspx?PRID=2243248&lang=2®=3
• PIB, India vaccine production and Vaccine Maitri: https://www.pib.gov.in/PressReleasePage.aspx?PRID=1931918&lang=2®=3
• Pharmexcil handbook: https://pharmexcil.com/uploadfile/Hand_Book_14_06_2025_final.pdf
